​Due diligence: On surrogate advertising

The issue of surrogate advertising—where a brand promotes a banned product (like tobacco or liquor) under the guise of an unregulated product (like pan masala or music CDs)—highlights significant challenges in regulatory enforcement. This editorial discusses the Maharashtra FDA's attempt to use the Consumer Protection Act 2019 to hold celebrity endorsers accountable. This Act is crucial as it introduced endorser liability, shifting away from the idea that celebrities can claim ignorance about a manufacturer's intent. The FDA's action represents an attempt to strengthen administrative capacity by tackling the root of the marketing strategy. However, the editorial cautions that regulatory action must be legally sound. The fragmented nature of India's regulatory framework, split across various Acts and agencies, often leads to judicial intervention, emphasizing the need for cohesive and robust governance reforms to effectively curb unfair trade practices without falling into regulatory overreach.

The FDA's actions must be viewed through the lens of legal precedents and the specific provisions of existing laws. The editorial cites the Delhi High Court judgment in DGHS vs Som Pan Product Pvt. Ltd. (2024), which establishes a high burden of proof on the state. It determined that the mere existence of a technically legal product (like Elaichi) does not automatically permit its advertisement if it acts as a surrogate for tobacco; however, the state must explicitly prove the surrogate nature of the advertisement. This highlights the delicate balance between commercial free speech and public health regulations. The state must utilize tools like the Cigarettes and Other Tobacco Products Act (COTPA) and the Food Safety and Standards Act 2006 meticulously. For UPSC Mains, understanding how statutory bodies interpret and apply these laws, and how the judiciary acts as a check against arbitrary executive action, is essential for answering questions on the effectiveness of regulatory frameworks.

Surrogate advertising poses a severe public health challenge, particularly in a country like India, which bears the world’s largest burden of oral cancer. The marketing strategies often exploit the persuasive power of celebrities to normalize brands associated with harmful products, creating a gross asymmetry where the endorser reaps financial benefits while the consumer bears the health costs. This issue intersects with the broader problem of inequities in the public health-care system, which struggles to manage the consequences of tobacco consumption. The FDA's stance that such advertisements constitute unfair trade practices is a vital step in protecting public health. This scenario underscores the necessity of stringent regulations not just for tobacco surrogates, but also for products making unsubstantiated health claims or misleading financial promises, highlighting the state's role in safeguarding consumer welfare.